Collective Download Patients 
CannaMD
MARCH 4, 2020
Releaf is a free mobile app to help patients track, learn from, and improve their use of medical cannabis. The data that is collected in Releaf App is used for multiple research studies and helps physicians identify what products patients are finding most effective. Patients can learn more by visiting ReleafApp.com.
Cannabis Law Report
AUGUST 3, 2021
Unlike most other ailments, there isn’t a simple test that physicians can use to diagnose a patient with a disorder. But, of course, the growth in the market will depend mainly on accurately diagnosing patients with certain mental illnesses and successfully treating those conditions with psychedelics. Medxtractor Corp.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Greencamp
FEBRUARY 17, 2019
Irritable bowel syndrome (IBS) is a collection of symptoms which create discomfort in the abdominal area, resulting in the inflammation of the digestive tract. During a three-month period, 13 patients with long-standing IBS were given cannabis. You can download the eBook here for free. What is IBS?
Cannabis Law Report
SEPTEMBER 15, 2021
This deceptive marketing of unproven treatments raises significant public health concerns because patients and other consumers may use them instead of approved therapies to treat serious and even fatal diseases. Of the 22 patients, 19 experienced adverse events after ingesting delta-8 THC-containing food products (e.g.,
The Cannigma
JANUARY 16, 2021
Listen & Subscribe: Finding the right cannabis product can be a daunting task for anyone, let alone a new medical patient without any guidance. You don’t really need to be a medical cannabis patient to experience anxiety and stress, especially in today’s world. So like example, anxiety or stress.
Cannabis Law Report
JUNE 30, 2021
Despite the high prevalence of these disorders, few patients are accurately screened and diagnosed. of patients with major depressive disorder, 92.7% of patients with bipolar disorder, 71% of patients with generalized anxiety disorder, and 97.8% of patients with social anxiety disorder. Building the Data Backend.
Cannabis Law Report
DECEMBER 9, 2021
The study involved 100 treatment-resistant patients and were randomized to psilocybin or the nicotine patch, each receiving the same cognitive-behavioral therapy. At 12 months, 59% of the patients who received the psilocybin treatment remained abstinent, while only 28% of those who received the nicotine patch remained abstinent.
Expert insights. Personalized for you.
Let's personalize your content